IL1B and hydrops fetalis: Analysis of the CANTOS phase III clinical trial data reveals that canakinumab (Ilaris), an anti-IL-1b monoclonal antibody, demonstrated a reduction in HF-related hospitalizations and mortality in post-MI patients [55].